At present, various giants in the IVD market are competing the five mainstream market segments: biochemistry, immunity, molecular, POCT, and clinical testing.

Since the end of 2019, biochemical diagnosis companies have faced severe challenges due to the impact of the political and economic environment.

As companies developed with biochemical reagents, BSBE, Leadman, Medicalsystem, Maccura, Dirui, and Zybio are still flourishing in the biochemistry field; they are also developing new products and expanding into other areas based on the biochemical diagnosis while maintaining the existing biochemical product lines.

In 2019, China's IVD market size exceeded 71 billion CNY, with a year-on-year growth of 15%, of which, the biochemical diagnosis market accounted for 23%; in 2020, China's IVD market size exceeded 100 billion CNY, of which, the biochemical diagnosis market accounted for 18%. Although the biochemical market share in 2020 is lower than that in 2019, the market size in 2020 has increased by nearly two billion CNY compared with 2019.

Zybio obtained the registration certificate and patent for the Lp-PLA2 assay kit (rate method) in 2015. The performance of the kit can reach the international leading level by using an innovative substrate design and reagent formula.

Against the background of the current rapid development of life science and technology, with the development of clinical biochemical test technologies, there are more and more product categories and test items in the biochemical detection platform.

Biochemical diagnosis is often used for the testing of basic items such as liver function, kidney function, blood glucose, and blood lipid. By measuring the content (activity) of specific biochemical substances, people's physical conditions can be assessed and the relevant causes can be identified.

Recently, Shanghai BioGerm Medical Technology Co., Ltd. reached a strategic consensus and completed the signing of a contract, in which BioGerm will formally enter the biochemical diagnostic field by wholly acquiring Kaisheng Biology.

Pointe Biotech (Nanjing) Co., Ltd. (hereinafter referred to as: Pointe) and its shareholders formally reached a strategic consensus and completed the signing of the contract